PLIANT THERAPEUTICS, INC. Interest Expense
PLIANT THERAPEUTICS, INC. (PLRX) reported Interest Expense of $445.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-06.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2024-05-06
- PLIANT THERAPEUTICS, INC. interest expense for the quarter ending 2024-03-31 was $445.00K, a 43.09% increase year-over-year.
- PLIANT THERAPEUTICS, INC. interest expense for the quarter ending 2023-12-31 was $321.00K, a 1.26% increase year-over-year.
- PLIANT THERAPEUTICS, INC. interest expense for the quarter ending 2023-09-30 was $317.00K, a 5.32% increase year-over-year.
- PLIANT THERAPEUTICS, INC. interest expense for the quarter ending 2023-06-30 was $319.00K, a 84.39% increase year-over-year.
- PLIANT THERAPEUTICS, INC. interest expense for fiscal 2023 was $1.27M, a 60.18% increase from fiscal 2022.
- PLIANT THERAPEUTICS, INC. interest expense for fiscal 2022 was $791.00K.
- PLIANT THERAPEUTICS, INC. interest expense for fiscal 2021 was $0.00.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2024-03-31 | $445.00K 10-Q · filed 2024-05-06 | $766.00K derived: sum of 2 quarters · filed 2024-05-06 | $1.08M derived: sum of 3 quarters · filed 2024-05-06 | $1.40M derived: sum of 4 quarters · filed 2024-05-06 |
| 2023-12-31 | $321.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $638.00K derived: sum of 2 quarters · filed 2024-02-27 | $957.00K derived: sum of 3 quarters · filed 2024-02-27 | $1.27M 10-K · filed 2024-02-27 |
| 2023-09-30 | $317.00K 10-Q · filed 2023-11-09 | $636.00K derived: sum of 2 quarters · filed 2023-11-09 | $946.00K 10-Q · filed 2023-11-09 | $1.26M derived: sum of 4 quarters · filed 2024-05-06 |
| 2023-06-30 | $319.00K 10-Q · filed 2023-08-09 | $630.00K 10-Q · filed 2023-08-09 | $947.00K derived: sum of 3 quarters · filed 2024-05-06 | $1.25M derived: sum of 4 quarters · filed 2024-05-06 |
| 2023-03-31 | $311.00K 10-Q · filed 2024-05-06 | $628.00K derived: sum of 2 quarters · filed 2024-05-06 | $929.00K derived: sum of 3 quarters · filed 2024-05-06 | $1.10M derived: sum of 4 quarters · filed 2024-05-06 |
| 2022-12-31 | $317.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $618.00K derived: sum of 2 quarters · filed 2024-02-27 | $791.00K derived: sum of 3 quarters · filed 2024-02-27 | $791.00K 10-K · filed 2024-02-27 |
| 2022-09-30 | $301.00K 10-Q · filed 2023-11-09 | $474.00K derived: sum of 2 quarters · filed 2023-11-09 | $474.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $173.00K 10-Q · filed 2023-08-09 | $173.00K 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |